Journals / Selçuk Tıp Dergisi / 2010 / Cilt: 26 - Sayı: 2

The effect of aromatase inhibitor therapy on serum total sialic acid levels in breast cancer patients

Aromataz inhibitörü tedavisinin meme kanserli hastalarda serum total siyalik asit düzeylerine etkisi

Pages
35–37
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We concluded that, aromatase inhibitor therapy results in a significant decrease in sialic acid levels which may be used as a prognostic marker in the treatment of breast cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:It was reported previously that serum total sialic acid levels were increased in various cancers including breast cancer.
📊
Key Findings & Data:Total sialic acid levels were determined in sera of 20 patients with breast cancer and treated with aromatase inhibitors.
💡
Conclusion & Impact:We concluded that, aromatase inhibitor therapy results in a significant decrease in sialic acid levels which may be used as a prognostic marker in the treatment of breast cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

It was reported previously that serum total sialic acid levels were increased in various cancers including breast cancer. We aimed to evaluate the effect of aromatase inhibitor therapy on serum total sialic acid levels in breast cancer patients. Total sialic acid levels were determined in sera of 20 patients with breast cancer and treated with aromatase inhibitors. Total sialic acid levels were determined by a colorimetric method. Serum total sialic acid levels were 15,06±2,71 mmol/ml and 8,17±5,31 mmol/ml at the beginning and three months after the treatment respectively. Thus, a significant decrease in total sialic acid levels was observed after the treatment (p<0,05). We concluded that, aromatase inhibitor therapy results in a significant decrease in sialic acid levels which may be used as a prognostic marker in the treatment of breast cancer.

Özet

Meme kanseri de dahil olmak üzere çeşitli kanserlerde serum total siyalik asit düzeylerinde yükselme olduğu daha önce yapılan çalışmalarda bildirilmiştir. Biz meme kanserli hastalarda, aromataz inhibitörü tedavisinin serum total siyalik asit düzeyine etkisini ortaya koymayı amaçladık. Total siyalik asit seviyeleri aromataz inhibitörleriyle tedavi edilen 20 meme kanser tanılı hastada kolorimetrik bir yöntemle ölçüldü. Serum total siyalik asit düzeyleri tedavi başlangıcında ve tedavinin 3. ayında sırasıyla 15,06±2,71 mmol/ml ve 8,17±5,31 mmol/ml olarak bulundu. Böylece tedavi sonrası total siyalik asit düzeylerinde anlamlı bir azalma gözlendi (p<0,05). Aromataz inhibitörü tedavisinin siyalik asit düzeylerinde anlamlı bir düşüşe neden olduğu ve bunun meme kanseri tedavisinde prognostik bir belirteç olarak kullanılabileceği sonucuna vardık.

🔖

Cite This Article

KIYICI, A., ARTAÇ, M., ÇİÇEKLER, H., EREN, Ö., MEHMETOĞLU, İ., BÖRÜBAN, C. (2010). The effect of aromatase inhibitor therapy on serum total sialic acid levels in breast cancer patients. Selçuk Tıp Dergisi, Cilt: 26 - Sayı: 2, 35–37. https://ajindex.com/articles/319139

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Özmen V. Breast cancer in the world and Turkey. Meme Sağlığı Dergisi 2008; 4(1):7-12
  2. Eti AF, Gürkan A. Kadınlarda meme kanseri risk düzeyi. Meme Sağlığı Dergisi 2007;3 (2):63-8
  3. Karamanoğlu YA, Gök ÖF. Mastektomili hastalarda evde bakım. Meme Sağlığı Dergisi 2008;4(1):3-8
  4. Monica M, Gautam J, David AP. Anastrozole use in early stage breast cancer of post-menopausal women. Clin Med Ther. 2009 Mar 31;1:141-56
  5. Süer GS, Kazezoğlu C, Tabakoğlu E, Altıay G, Güngör Ö, Türe M. The importance of serum total and lipid-bound sialic acid as markers in patients with small cell and non-small cell lung carcinoma. Trakya Universitesi Tıp Fakültesi Dergisi 2007; 24(2):101-8
  6. Warren L. The thiobarbituric acid assay of sialic acids. J Biol Chem 1959; 234:1971-5
  7. Celen O, Yildirim E, Ozen N, Sonmez C. Predictive value of relative changes in serum total sialic acid level for response to neoadjuvant chemotherapy in patients with locally advanced breast carcinoma. Neoplasma 2006;53(4):347-51
  8. Stringou E, Chondros K, Kouvaris J, Kakari S, Papavassiliou K. Serum sialic acid (TSA/LSA) and carcinoembryonic antigen (CEA) levels in cancer patients undergoing radiotherapy. Anticancer Res 1992;12(1):251-5
  9. Basoglu M, Atamanalp SS, Yildirgan MI, et al. Correlation between the serum values of soluble intercellular adhesion molecule-1 and total sialic acid levels in patients with breast cancer. Eur Surg Res 2007;39(3):136-40. Epub 2007 Mar 2
  10. López Sáez JJ, Senra-Varela A. Evaluation of lipid-bound sialic acid (LSA) as a tumor marker. Int J Biol Markers 1995;10(3):174- 9
  11. Balo NN, Ishaq M. Pak J. Serum sialic acid and glycoprotein levels in some Libyan cancer patients. Pharm Sci 1991;4(1):43-8
  12. O’Kennedy R, Berns G, Moran E, Smyth H, Carroll K, Thornes RD, O’Brien A, Fennelly J, Butler M. A critical analysis of the use of sialic acid determination in the diagnosis of malignancy. Cancer Lett 1991;58(1-2):91-100
  13. Romppanen J, Eskelinen M, Tikanoja S, Mononen I. Total and lipid-bound serum sialic acid in benign and malignant breast disease. Anticancer Res 1997;17(2B):1249-53
  14. Patel PS, Raval GN, Rawal RM, Patel MM, Balar DB, Patel DD. Importance of glycoproteins in human cancer. Indian J Biochem Biophys 1997;34(1-2):226-33
  15. Patel PS, Baxi BR, Adhvaryu SG, Balar DB. Evaluation of serum sialic acid, heat stable alkaline phosphatase and fucose as markers of breast carcinoma. Anticancer Res 1990;10(4):1071-4
  16. Adamo V, Altavilla G, Caristi N